当前位置: 首页 > 期刊 > 《中国实用医药》 > 2014年第13期 > 正文
编号:12709379
诺氟沙星三联疗法根除幽门螺杆菌的疗效观察(2)
http://www.100md.com 2014年5月5日 刘爽
第1页

    参见附件。

     诺氟沙星为第三代氟喹诺酮类抗菌药, 具有广谱抗菌作用, 尤其对需氧革兰阴性杆菌活性高, 诺氟沙星体外对多重耐药菌亦具抗菌活性。诺氟沙星为杀菌剂, 通过作用于细菌DNA螺旋酶的A亚单位, 抑制DNA的合成和复制而导致细菌死亡[4]。诺氟沙星口服吸收良好、血药浓度高、组织渗透性强、体内不易失活、不良反应少[5]。阿莫西林与诺氟沙星同属第一类杀菌剂, 它们之间联用呈协同作用[6], 因此本研究采用埃索美拉唑、阿莫西林和诺氟沙星三联疗法根除HP, 与对照组相比显著提高了HP根治率(86.5% VS 63.5%), 差异有统计学意义(P<0.05), 其中对于胃溃疡的患者, 采用诺氟沙星三联疗法根治率达93.3%, 显著高于对照组。

    参考文献

    [1]Xu S, Wan X, Zheng X, et al. Symptom improvement after helicobacter pylori eradication in patients with functional dyspepsia- A multicenter, randomized, prospective cohort study. Int J Clin Exp Med, 2013,6(9):747-756.

    [2]Asaoka D, Nagahara A, Matsuhisa T, et al. Trends of second-line eradication therapy for Helicobacter pylori in Japan: a multicenter study in the Tokyo metropolitan area. Helicobacter, 2013,18(6):468-472.

    [3]Fan HY, Wang J, Yan GC, et al. Increasing gastric juice pH level prior to anti-Helicobacter pylori therapy may be beneficial to the healing of duodenal ulcers. Exp Ther Med, 2013,5(3):912-916.

    [4]Rimbara E, Noguchi N, Kawai T, et al.Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB.Helicobacter, 2012,17(1):36-42.

    [5]Shaikh AR, Giridhar R, Megraud F, et al. Metalloantibiotics: synthesis, characterization and antimicrobial evaluation of bismuth-fluoroquinolone complexes against Helicobacter pylori. Acta Pharm, 2009,59(3):259-271.

    [6]Oyedeji KS, Smith SI, Coker AO, et al. Arigbabu AO. Antibiotic susceptibility patterns in Helicobacter pylori strains from patients with upper gastrointestinal pathology in western Nigeria. Br J Biomed Sci, 2009,66(1):10-13.

您现在查看是摘要介绍页,详见PDF附件